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ABSTRACT 
OBJECTIVE. To understand the efficacy of cladribine treatment in multiple sclerosis (MS) through 
analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine 
and alemtuzumab induction-therapies. 
METHODS. The regulatory submissions of the CLARITY (NCT00213135) cladribine and CARE-MS I 
(NCT00530348) alemtuzumab trials were obtained from the European Medicine Agency through 
Freedom of Information requests. Data was extracted and statistically analysed. 
RESULTS. Either dose of cladribine (3.5mg/kg; 5.25mg/kg) tested in CLARITY reduced the annualised 
relapse rate to 0.16-0.18 over 96 weeks, and both doses were similarly effective in reducing the risk of 
MRI lesions and disability. Surprisingly, however, T cell depletion was rather modest. Cladribine 
3.5mg/kg depleted CD4+ cells by 40-45% and CD8+ cells by 15-30%, whereas alemtuzumab suppressed 
CD4+ cells by 70-95% and CD8+ cells by 47-55%. However, either dose of cladribine induced 70-90% 
CD19+ B cell depletion, similar to alemtuzumab (90%). CD19+ cells slowly repopulated to 15-25% of 
baseline before cladribine re-dosing. However, alemtuzumab induced hyper-repopulation of CD19+ B 
cells 6-12months after infusion, which probably forms the substrate for B cell autoimmunities 
associated with alemtuzumab. 
CONCLUSIONS. Cladribine induced only modest depletion of T cells, which may not be consistent with 
a marked influence on MS, based on previous CD4+ T cell depletion studies. The therapeutic drug-
response relationship with Cladribine is more consistent with lasting B cell depletion and, coupled with 
the success seen with monoclonal CD20+ depletion, suggests B cell suppression could be the major 
direct mechanism of action.   
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INTRODUCTION 
Multiple sclerosis (MS) is a central nervous system demyelinating disease responding to 
immunosuppression1. Pulsed induction-therapies with cladribine (CLAD)2,3 and alemtuzumab (ALEM)4-6 
can induce long-term remission3,6, whilst reducing risks of a permanent immunosuppressive-state 
through continuous drug-use7. Pivotal trials of an oral CLAD, 2-chlorodeoxyadenosine triphosphate, 
prodrug8 and ALEM, CD52-depleting antibody9, suggest that both drugs have comparable clinical 
efficacy in controlling relapses2-5, but markedly-different side-effect profiles2,4,5.  Whilst both drugs 
induce lymphocyte depletion8-11, only ALEM causes significant secondary B cell autoimmunity (SAI) in 
people with MS6,9. It was suggested that CLAD may create a cancer risk2, which in the absence of 
additional trial data caused regulators to refuse licencing and halted CLAD development in 201112. 
However, a subsequent CLAD trial13 and meta-analysis14 indicated that the CLAD-associated cancer 
frequency was no different to natural aging or other pivotal MS-drug trials14. This suggested that even 
in the absence of oral CLAD, injectable generic CLAD, may still have value in treating active MS15,16.  
 
Whilst the mechanism of action of CLAD in MS is unclear17, efficacy of ALEM has been attributed to 
CD4+ T cell deletion and relative-sparing of T regulatory cells9,18 and SAI to homeostatic T cell 
proliferation and lack of thymic repopulation19. Whilst immune-reconstitution kinetics after ALEM have 
been reported10,18,20, the lymphocyte-subset of pivotal CLAD/ALEM trials were only partially 
disclosed2,4,5, yet meeting-abstracts indicated that lymphocyte subset data was collected and analysed 
years ago21,22.  We hypothesised that differences in the CLAD/ALEM lymphocyte repopulation kinetics 
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METHODS 
Standard Protocol Approvals, Registrations, and Patient Consents. 
Freedom of Information (FOI) requests to the European Medicines Agency (EMA) for the full regulatory 
submissions of phase III “CLAD tablets treating multiple sclerosis orally” (CLARITY; NCT00213135)2 and 
“Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, study one” (CARE-MS I; 
NCT00530348)4 trials were made. Whilst these trials were recruited following ethical approval of the 
trials and informed consent, as previously reported2,4, no specific ethical approval was obtained or 
required to view and use these “public domain” documents. The details of participants were 
anonymous. Information relevant to: study design, setting, participants, eligibility, variables, 
randomization, blinding, study size, bias reduction, flow diagrams of participants and the CONSORT 
and STROBE reporting guidelines can be obtained from the original CLARITY2 and CARE-MS I4 
publications.  
Trial Designs 
The full details of the trials have been reported previously2,4. Briefly, in the 96 week CLARITY trial 
people with relapsing MS (pwRMS) were randomized 1:1:1 to receive either placebo, or one of two 
doses of oral CLAD. Patients were given tablets containing either 10mg/day (60-69.9kg body weight) or 
20mg/day (70-79kg body weight) CLAD prodrug administered for 4-5 days in weeks 0 and 5 (year 1) 
and weeks 48 and 52 (year 2) to result in a total cumulative dose of 3.5mg/kg.  Those randomized to 
the 5.25mg/kg arm were given additional doses in weeks 9 and 132. In the CARE-MS I, pwRMS were 
randomly allocated 1:1 to receive either interferon β-1a (Rebif 44mg tiw) or ALEM 12mg/day on days 
1-5 in year 1, followed by 12mg/day on days 1-3 one year later4.  
Freedom of Information Requests 
After termination of the commercial development of oral CLAD in 2011, and subsequent conversations 
with the UK Medicines and Healthcare products Regulatory Agency about approaches to develop 
generic CLAD, the full regulatory submission of the CLARITY trial2 was obtained through a FOI request 
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(Submitted May 2013, obtained November 2013). The dataset was provided in portable document 
format (pdf). Files containing relevant data were identified and converted into Microsoft Excel 
spreadsheets using a pdf parser developed on a Python 2.7 platform at the MidPlus computational 
facilities at Queen Mary University of London (code available on request). The converted data was 
validated by comparing sample records between pdf and spreadsheet versions of the files. In addition 
we obtained redacted copies of the regulatory submission of the CARE-MS I trial4. The data was 
provided in pdf batches during the third and forth quarter 2016.  However primary (raw) white cell 
counts were not included in this package. The data presented here were therefore extracted from the 
tabulated documents. 
Lymphocyte Phenotyping data 
In both CLARITY and CARE-MS I, lymphocyte subsets were analysed using flow cytometry. Both 
datasets included the following: CD3+, CD4+ and CD8+ T cells, CD19+ B cells, CD16+/CD56+ (Natural Killer 
NK) cells; CD4+/CD45RA+ (naïve T helper) cells; CD4+/CD45RO+ (memory T) cells. The data was 
presented as absolute numbers/unit volume in both studies.   
Statistical Analysis 
Statistical analysis comparing two or more unpaired independent nominal variables was performed 
using chi-square test for heterogeneity. If statistical significance was detected for comparison of more 
than two variables post-hoc chi-square test for heterogeneity with Bonferroni correction for multiple 
comparisons was applied. Data is represented as mean ± standard deviation (SD) unless described 
otherwise. For comparison of unpaired independent continuous variables two-tailed Student’s t test 
for unpaired samples assuming unequal variances was used. For comparison of more than two 
unpaired independent continuous variables one way analysis of variances (ANOVA) with post-hoc 
Tukey was used.  It was evident that the whole population was not analysed at every time point as 
indicated in the text, no adjustments for such missing data were made.  
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RESULTS  
In total, 309/1326 pwRMS from the CLARITY trial2 had lymphocyte subsets analysed (Figure 1), with n= 
101 in the placebo arm, n=103 in the CLAD 3.5mg/kg arm, and n=105 in the CLAD 5.25mg/kg arm 
(Supplementary Table e-1 and Table e-2). There was no significant difference for any demographics or 
clinical characteristics among the study arms (Table e-2). Importantly, compared to placebo, both 
doses of CLAD caused significant and comparable (p=0.953, ANOVA post-hoc Tukey) reduction in the 
annualised relapse rate (relative reduction compared to placebo 55% and 61% for CLAD 3.5mg/kg and 
5.25mg/kg, respectively, over 96 weeks) and MS-related magnetic resonance imaging parameters 
(Table e-2). The sample was representative of the overall population in the CLARITY study2. 
 
Full blood count 
Following administration of CLAD only minor and non-significant depletion of platelets and red blood 
cells occurred. However, there was significant (p<0.01) depletion of the total leukocyte population 
within a month of the second cycle of both doses of CLAD (Figure 1A). As expected, lymphocytes 
(Figure 1B)2 were markedly depleted over the 96 weeks observation period (p<0.01) compared to 
more subtle influences on monocytes (Figure 1C), polymorphonuclear neutrophils (Figure 1D)2, 
eosinophils (Figure 1E) and basophils (Figure 1F). Following lymphocyte depletion with two doses of 
CLAD there was further depletion following use of two additional doses (Figure 1B).  
 
Lymphocyte phenotyping 
Whilst reduction of CD3+ T cells showed some dose-dependency (Figure 2A), depletion of CD19+ B cells 
was very similar with both dosing schedules (Figure 2B). B cells numbers dropped markedly following 
the first course of CLAD with a nadir (85-90% depletion) at the time of the second dose of cycle one. B 
cells did not drop further following administration of additional CLAD doses as part of the 5.25mg/kg 
schedule and recovered to 30% baseline prior to the second treatment cycle after 48 weeks, which 
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again led to significant depletion (80% baseline; Figure 2B). In contrast to the B cell population, a dose-
response effect with CD4+ and CD8+ T cells was detected (Figure 2, C and D). In the 3.5mg/kg group 
CD4+ T cell depletion by 20% occurred following the first dose, and by 45% following the second dose 
of cycle one. This level of depletion was maintained until the second cycle of treatment was given, 
which led to a maximum depletion by 60% baseline, over the duration of the study (96 weeks). In the 
5.25mg/kg group depletion was more pronounced, by 70% of baseline after the first cycle, remaining 
at this level until the end of the observation period (Figure 2C). CD8+ T cells followed a rather similar 
kinetic as CD4+ T cells though depletion was overall less pronounced. In the 3.5mg/kg group CD8+ T 
cells were reduced by 30% and 40% baseline following treatment cycles 1 and 2, respectively. In the 
5.25mg/kg group CD8+ T cells were reduced by 50% baseline after the first treatment cycle with no 
further depletion following the second cycle. Again similar to CD4+ T cells, CD8+ T cells did not show 
any significant recovery during the observation period (Figure 2D). The two CD4+ T cell subsets 
analysed (naïve, i.e. CD45RA+ and memory, i.e. CD45RA-) T cells were both affected and revealed 
rather similar kinetics of depletion and recovery (Figures 2E, 2F). In the 3.5mg/kg group naïve T cells 
were depleted by 45% and 60% baseline following treatment cycles 1 and 2, respectively (Figure 2E) 
with reductions in memory T cells being slightly less pronounced (Figure 2F). Maximum reduction of 
naïve T cells in the 5.25mg/kg group was by nearly 80% baseline within 12 weeks after treatment cycle 
1, subsequently remaining at 70% throughout the remainder of the study, whilst memory T cells 
described a similar curve of depletion and (minor) recovery at 60-65%. Three months after treatment 
initiation naïve CD8+ T cells in the 3.5mg/kg group were reduced by 26.5% and memory CD8+ T cells by 
less than 10% of baseline levels. No difference in CD3, CD4, CD8, or CD19 lymphocyte counts was 
detected between the patient cohorts remaining free of relapses and patients who developed at least 
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Comparison of lymphocyte kinetics after cladribine and alemtuzumab administration 
Although the demographics of pwRMS were different between CLARITY2 and CARE-MS I4 studies (Table 
e-1), both CLAD and ALEM exhibited high efficacy2-5.  However, analysis of lymphocyte subsets 
following CLAD and ALEM treatment revealed several differences (Figure 4). (i) One month after the 
first treatment cycle with ALEM CD4+ T cells were almost completely (by over 95% baseline) depleted 
(Figure 4A). Even one year after treatment, just before the second treatment cycle, CD4+ T cells 
remained depleted by over 70% of baseline. The 5.25mg/kg dose of CLAD led to reduction of CD4+ T 
cells by 70% baseline within three months, with very little recovery until the second treatment cycle 
nearly nine months later. (ii) With the 3.5mg/kg dose of CLAD, which was clinically as effective as the 
5.25mg/kg dose3,4 (Table e-2), depletion of CD4+ T cells during year one was much less pronounced 
than with ALEM or CLAD  5.25mg/kg. The gap between the CD4+ T cell depletion curves induced by the 
two different CLAD  dosing schedules only narrowed during year 2, though neither dose ever caused a 
nadir similar to ALEM (reduction by >90% baseline). (iii) The kinetics of CD8+ T cell depletion was 
comparable for both ALEM and CLAD (high and low doses) to their respective CD4+ T cell behaviour 
(Figure 4B). (iv) Whilst ALEM, as well as both doses of CLAD, induced depletion of NK cells, this cell 
type rapidly recovered following ALEM treatment, and were even slightly above baseline at 6 and 12 
months. In contrast, both doses of CLAD caused pronounced and virtually identical NK cell depletion, 
by 47% of baseline, within nine weeks of treatment cycle 1 (n= 71-72) (Figure 4C). (v) The most striking 
difference became evident comparing the effect of ALEM and CLAD on the CD19+ B cell population 
(Figure 4D). Whilst the level of depletion was initially similar between ALEM and both doses of CLAD, 
the repopulation characteristics were very different. After CLAD, B cells slowly repopulated, remaining 
significantly below their baseline level until the second treatment cycle reduced this subset yet again. 
In contrast, B cell numbers after ALEM repopulated back to baseline within less than six months and 
then hyper-repopulated well above baseline by nine and 12 months (Figure 4D). Surprisingly, neither 
of the peer-reviewed phase III trial reports of ALEM in MS provided any indication of the latter, but 
only reported that B cells reach normal levels six months after drug administration4,5. 
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DISCUSSION 
We analysed the lymphocyte repopulation kinetics following depletion with oral CLAD prodrug and 
intravenous ALEM using datasets from their regulatory submissions. Using data mining of these 
publicly available documents it was possible to obtain additional information not previously published 
in peer-reviewed papers. This may provide value for understanding the mechanisms of action and side-
effect profiles of these disease modifying therapies (DMT), which have focused on the pathogenic role 
of T cells23. However, the therapeutic drug-response relationship with CLAD is perhaps more consistent 
with lasting B cell depletion of both doses and helps create a focus on the role of the B cells in control 
of MS, which may or may not act via T cells24. The data obtained with alemtuzumab is consistent with 
previous smaller scale studies10,25   
There is unequivocal evidence from the marked induction of disease following haematopoietic stem 
cell treatment that relapsing MS is due to aberrant function of the immune system26. CLAD induced a 
modest depletion in T and NK cells, but a more marked depletion of B cells. This was consistent with 
the known selective lymphocyte depleting effect, because they express high levels of deoxycytidine 
kinase that phosphorylates CLAD, a deoxyadenosine analogue, to cytotoxic 2-chlorodeoxyadenosine 
triphosphate8. Although causality was not proven, the phase III trial data may suggest that lymphocyte 
depletion contributes to the reduction in disease activity in pwRMS2,3. CLAD also effectively inhibited 
the evolution from a clinically-isolated syndrome of demyelination to definite MS13. Most of the 
ongoing disease activity in that trial occurred within the first three months of the study13. Based on the 
data presented here, maximum depletion using the dosing schemes employed takes between one and 
three months. Re-baselining of efficacy data at three months after first treatment course would have 
made the suppression of disease activity even more impressive13. Furthermore, the slower depletion 
kinetics of CLAD probably contributes to the lack of administration-related reactions with CLAD that 
are reported in approximately 90% of pwRMS treated with ALEM4,5.  
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Whilst MS has commonly been considered to be a CD4+ T cell (Th1/Th17) mediated disease23, a 
concept supported by the marked (95%) CD4+ T cell depletion induced by ALEM, CD4+ T cell depletion 
in isolation has arguably failed to control MS24,27. Depletion of CD4+ T cells using a CD4-specific 
antibody, dosed to maintain CD4+ T cell numbers above 250 cells/mm3 (equivalent to a depletion of 
about 70%) to limit immunodeficiency thresholds27, did not effectively suppress the development of 
new lesions on MRI, and was considered to have failed in MS27. Based on our analysis, the 45-50% 
depletion of CD4+ T cells achieved by CLAD 3.5mg/kg, leaves these cells above the threshold required 
for optimal disease inhibition in both CD4 T cell-mediated experimental autoimmune 
encephalomyelitis in animals28, and MS27. Therefore, CD4+ T cell depletion may not account for the 
efficacy of this drug, in terms of relapse reduction and its effect on new MRI lesions, given a strong 
treatment effect of CLAD was already detectable within the first year of treatment2,3,13. 
 
The perceived failure of CD4 depleting monoclonal antibody led some groups to speculate that CD8+ T 
cells may be the pathogenic drivers of MS as suggested by the predominance of this cell type in MS 
lesions29.  Again, given the depletion threshold established for CD4 depletion27,28, we hypothesize this 
is unlikely to be a key mechanism of action of CLAD, given CLAD 3.5mg/kg had only a minor (15-28%) 
CD8+ T cell depleting effect in year 1, when a strong disease modifying effect was already evident3,13.  
However, again this comes with the proviso an effective threshold of CD8+ T cell depletion required for 
effective immunotherapy in MS, has yet to be defined. In contrast, ALEM markedly depletes CD8+ T 
cells. This, coupled with depletion of other immune subsets, may potentially contribute to the high 
number of reported infections that occurred in 77% of pwRMS participating in the CARE-MS I trial, 
compared to only 48% in the CLARITY trial2,4. In addition, ALEM is more likely to effect CD8+ 
regulatory/suppressor cell responses that can control tolerance and potential SAI induction28.  
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Whilst it has been shown that the cancer rate in pwRMS on CLAD was no different compared to all 
contemporaneously-licensed DMT14, NK cells represent an important part of cancer 
immunosurvelliance. As CLAD induced a modest depletion of NK cells, vigilance is therefore advised 
over the intermediate and longer-term to truly establish safety, whether or not oral CLAD becomes a 
licensed DMT for pwRMS, or a generic preparation of CLAD is being used off-label16,30.   
 
CLAD induced a marked and long-lasting CD19+ B cell-depletion that did not reach baseline levels 
within the 12 month treatment cycle, a repopulation-kinetic evidently contrasting with ALEM. Whilst 
the capacity of ALEM for hyper-repopulation of B cells has been reported previously10,20, it was 
subsequently largely ignored, notably in the phase III trial reports4,5. We have recently reported that 
CD8+ T cell-depletion by CD52-specific antibodies can block immunological tolerance induction28, 
suggesting it could contribute to the rapid hyper-repopulation of B cells that may be the prelude of 
SAI. Such hyper-repopulation of CD19+ B cells is not a feature of treatment with CLAD or CD20-specific 
B cell-depleting therapies31 neither of which are associated with B cell-driven autoimmunities2,32 or 
significant T cell depletion31. Following ALEM, the CD19+ B cell hyper-repopulation into the blood is due 
to the accumulating immature B cells, probably from the bone marrow, where they differentiate into 
mature/naïve B cells20. When this occurs in the absence of T cell regulation, previous studies have 
shown that B cell autoreactivity can develop, and this may be a cause of SAI following use of ALEM in 
pwRMS33,34. Previously, it has been shown that the apparent increase in the number of CD19+ B cells 
generated by the over-production of immature/mature B cells following ALEM infusion, masks a long-
lasting depletion of CD19+/CD27+ memory B cells20, which also occurs to varying levels with other 
agents that control MS24, 31, suggesting that these cells may be important in disease control by DMT24. 
However, it must be recognised that there are limitations of solely examining peripheral blood immune 
subset levels, when it is likely that the pathogenic cells form only a minor population within any one 
subtype. It is therefore perhaps not be surprising that peripheral blood CD4+, CD8+ and CD19+ cell 
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levels have not demonstrated biomarker activity to predict disease activation following immune 
reconstitution after CLAD and ALEM treatment25, suggesting that further functional analysis may be 
required to define the mechanisms of action. Furthermore, without access to all of the primary data, 
we were unable to directly compare all of the subset analysis performed to clinical efficacy and safety, 
so their true relationship remains to be established. The lack of peripheral blood biomarker activity 
may also be due to compartmentalisation of autoimmunity outside of the peripheral blood. This could 
be due to the actions of immune cells sequestered within the CNS during MS, which trigger disease 
activity24. Alternatively, compartmentalisation of the immune response within lymphoid tissues may 
also be a reason for the inability to detect a biomarker of autoimmune activity within the blood. As 
such it is of interest that sequestration of immune cells in lymphoid tissue, such as in the spleen and 
notably bone marrow, following spingosine-1-phosphate receptor modulation35 may limit the capacity 
of ALEM to control MS36, as ALEM may deplete less-effectively in lymphoid tissues compared to the 
blood36,37.  Alternatively, it is possible that the important pathogenic cells may not yet have been 
adequately analysed as it is likely they form only a small component within the pool of immune cells. 
Furthermore, it appears that in addition of any T cell inhibitory activity23, most agents that inhibit MS 
also deplete memory B cells24.  Relating levels of memory B cells to therapeutic activity has yet to be 
performed in MS, but this has been used to personalise retreatment to limit relapse in other 
autoimmune diseases that are sensitive to CD20-depleting antibodies38,39. Whilst it is clear that ALEM 
markedly depletes memory B cells20, the memory B cell depleting capacity of CLAD is unknown. It is 
tempting to speculate that suppression MS disease-activity by CLAD may relate to long-term depletion 
of memory B cells.  Further work, including functional studies and cytokine analysis, additional to that 
already known9,17,18 will be required to fully understand the definitive mechanism of action of these 
treatments, as both qualitative and quantitative changes in lymphocyte subsets will be important in 
defining their therapeutic activity9,18. 
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FIGURE LEGENDS 
Figure 1. Cladribine targets mainly lymphocytes. 
Mean number of red blood cells and leucocytes following treatment with either placebo (n=42-101. 
Typically the lower limit of sample size was n=63, except week on 55) or a total doses of either 
3.5mg/kg (n=47-103. Typically the lower limit of sample size was n=67, except on week 55) or 
5.25mg/kg (n=38-104. Typically the lower limit of sample size was n=62, except on week 55) Placebo 
(Circle) or CLAD that was administered in monthly courses (Inverse triangle) at 0, 5 and 48 and 52 
weeks (Diamond. 3.5mg/dose) and additionally at 9 and 13 weeks (Hexagon. 5.25mg/dose). The results 
show the mean ± SEM of (A) Red blood cells (B) platelets (C) White blood cells, (D) Lymphocytes, (E) 
Monocytes, (F) polymorphonuclear neutrophils, (G) eosinophils or (H) basophils. 
 
Figure 2 Cladribine preferentially depletes B lymphocytes compared to a modest depletion of T cells.  
The results represent the mean percentage ± SEM of blood lymphocytes compared to baseline 
following treatment with either placebo (Circle; n= 56-79) or total doses of either 3.5mg/kg (Diamond; 
n= 62-82) or 5.25/kg (Hexagon; n= 66-81) CLAD administered in monthly courses (inverse triangle) at 0, 
5, 48 and 52 weeks (3.5mg/dose) and additionally at 9 and 13 weeks (5.25mg/dose). Results show the 
numbers of (A) CD3+ T cells, (B) CD19+ B cells, (C) CD4+ T cells (D) CD8+ T cells and (E) CD4+ naïve and 
(F) CD4+ memory T cells. 
 
Figure 3 The incidence of relapse does not related to peripheral blood CD3, CD4, CD8, CD19, T and B cell 
levels. 
CLAD was administered as weekly courses at 0, 5 and 48 and 52 weeks. The results represent the mean 
± SEM absolute number (per mm3) of peripheral blood: (A) CD3, (B) CD19, (C) CD4 (D) CD8 lymphocytes 
following treatment (inverse triangles) with oral CLAD in the CLARITY trial administered with 3.5mg/kg 
CLAD and those divided into groups that remained healthy (Circle. n=121-136/group) or those that had 
a least one relapse (Diamond. n=29-34). 
 
Figure 4 Depletion of lymphocyte subsets following alemtuzumab and cladribine treatment  
CLAD was administered as weekly courses of CLAD at 0, 5 and 48 and 52 weeks (Time of initiation of 
cycle. Inverse triangle) or weekly courses of alemtuzumab at 0 and 52 weeks. The results represent the 
mean absolute number of peripheral blood lymphocytes (per mm3) during the CLARITY trial in pwRMS 
treated with either placebo (circle; n= 68-80), CLAD 3.5mg/kg (grey diamond; n= 77-86), CLAD 
5.25mg/kg (Hexagon; n= 79-84) and pwMS in the CARE-MS I trial treated with 12mg/day ALEM 
(Squares; n= 171-184).  
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Demographic and clinical characteristics of people participating in the CLARITY oral CLAD and the CARE-
MS I alemtuzumab phase III trials, whose lymphocyte subsets were collected. 
 











N  pwMS 101 103 105 376 
Age (yr)                                 39 ± 10 38 ± 11 41 ± 10 33 ± 8 
Male 









Weight (kg)                          70 ± 16 69 ± 14 70 ± 16 73 ± 17 
N white (%) 
N black (%) 













N pwMS previous DMT use (%)   31 (31%) 20 (19%) 29 (28%)  0 (0%) 
Disease duration (yr)        9 ± 8 7 ± 8 10 ± 8 2 ± 1 
Mean EDSS ± SD  3.2 ± 1.3 3.0 ± 1.3 3.3 ± 1.4 2.0 ± 0.8 
N pwMS Gd+ lesions (%)                 26 (26) 31 (30) 26 (25) - 
N Gd+ lesions on T1 MRI  0.7 ± 1.6 0.7 ± 2.1 1.0 ± 3.0 2.3 ± 5.1 
T1 (Hypointense) Lesion volume    - - - 1.2±2.1 cm3 
T2 (Hyperintense) Lesion volume     14.2 ± 12.6 ml 15.6 ± 16.7 ml 17.1 ± 18.0 ml 7.4 ± 9.2cm3 
 
Demographic data from people having lymphocyte subset analysis from the phase III CLARITY trial of 
oral CLAD and the CARE-MS I trial of ALEM. The results report mean ± SD unless otherwise indicated. 
Differences between three arms of the CLARITY study are not significantly different as assessed by 
ANOVA/chi-squared analysis. Raw data from the CARE-MS-I trial were not supplied. 
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Table e-2  








Annualised relapse rate 0.40 0.18 0.16 
Relative reduction vs. placebo*  55.4%     p=0.01 61.0%       p=0.004  
ANOVA (Post hoc Tukey) P=0.002    2v3 p= 0.953 
pwRMS with no relapse (%) 66 (65.3) 82 (79.6) 84 (80.0) 
Odds ratio for CLAD vs. placebo**  2.07     p=0.022 2.12      p= 0.018 
Chi Square p=0.022 Post-hoc Chi square    2v3 p= 0.944 
N patients with no relapse at 96 week N(%) 66 (65.3) 82 (79.6) 84 (80.0) 
N patients with 1 relapse at 96 week N(%) 14 (13.9) 15 (14.6) 16 (15.2) 
N patients with 2 relapses at 96 week N(%) 15 (14.9) 5 (4.9) 4 (3.8) 
N patients with 3 relapses at 96 week N(%) 4 (4.0) 1 (1.0) 0 (0.0) 
N patients with ≥4 relapses at 96 week N(%) 2 (2.0) 0 (0.0) 1 (1.0) 
Mean no. of relapses at 96 weeks ±SD 0.65 ±1.1 0.27 ±0.60 0.27 ±0.62 
ANOVA p=0.00048 (Post hoc Tukey) 1v2 p= 0.0021 1v3 p= 0.0017 2v3 p= 1.00 
Rescue therapy.  No. (%) 7 (6.9) 4 (3.9) 4 (3.8) 
Odds ratio for CLAD vs. placebo*χ2 =0.50  0.54 0.53 
EDSS progression. N (%)                        χ2 =0.75 19 (18.8) 16 (15.5) 16 (15.2) 
pwRMS with new Gadolinium+ Lesions no. (%) 59 (58.4) 28 (27.2) 27 (25.7) 
Post-hoc Chi square (p= 0.0021)  1v2 p= 0.0060 1v3 p= 0.0016 2v3 p=0.68 
Mean no. new Gadolinium+ Lesions ± SD 0.41 0.15  0.15 
ANOVA p=0.00035 (Post-hoc Tukey) 1v2 p= 0.0010 1v3 p= 0.0022 2v3 p= 0.97 
Mean change in T2 weighted lesion volume  -12.1 ± 79.5 -15.1 ± 44.9 -33.3 ± 55.7 
ANOVA p=0.035 (Post-hoc Tukey) 1v2 p= 0.94 1v3 p= 0.046 2v3 p=0.098 
Adverse Events (N) 71 P=0.027 81 90 
Moderate Adverse Events (N) vs. CLAD 39 p=0.018 47 54 
Severe Adverse Events(N) vs. CLAD 7 p=0.29 6 12 
Serious Infections vs. CLAD 18 p=0.72 23 22 
Lymphopenia  Reported as Adverse Event (N)  3 P<0.001 27 43 
Post-hoc Tukey groups: 1= placebo, 2= CLAD 3.5mg/kg, and 3= CLAD 5.25mg/kg.  * Odds of event 
occurring were calculated as the number of patients with the event divided by those without the event. 
The odds ratio was calculated as the odds in the groups treated with CLAD divided by the odds in the 
placebo group.  **The relative reduction was calculated as the ratio of the difference in the measures in 
the groups treated with CLAD and placebo group to the measure of the placebo group.  
